Perceived experiences of people with severe haemophilia A switching from factor VIII prophylaxis to emicizumab

Myrin-Westesson, Linda; Olsson, Anna

Perceived experiences of people with severe haemophilia A switching from factor VIII prophylaxis to emicizumab

The Journal of Haemophilia Practice

Volume 12 (2025): Issue 1 (January 2025)

By:

Linda Myrin-Westesson

and Anna Olsson

Open Access

|Sep 2025

References

Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26(Suppl 6): 1–158. doi: 10.1111/hae.14046.
Open DOI Search in Google Scholar Back to article
Davari M, Gharibnaseri Z, Ravanbod R, Sadeghi A. Health status and quality of life in patients with severe hemophilia A: A cross-sectional survey. Hematol Rep 2019; 11(2): 7894. doi: 10.4081/hr.2019.7894.
Open DOI Search in Google Scholar Back to article
O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes 2018; 16(1): 84. doi: 10.1186/s12955-018-0908-9.
Open DOI Search in Google Scholar Back to article
Poenaru D, Sandulescu MI, Cinteza D. Intraarticular management of chronic haemophilic arthropathy. Biomed Rep 2023; 19(3): 59. doi: 10.3892/br.2023.1641.
Open DOI Search in Google Scholar Back to article
Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost 2021; 19(9): 2112–2121. doi: 10.1111/jth.15444.
Open DOI Search in Google Scholar Back to article
Witkop M, Guelcher C, Forsyth A, et al. Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18–30 years) with hemophilia. Am J Hematol 2015; 90(S2): S3–S10. doi: 10.1002/ajh.24220.
Open DOI Search in Google Scholar Back to article
Wiley RE, Khoury CP, Snihur AWK, et al. From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia 2019; 25(3): 433–440. doi: 10.1111/hae.13754.
Open DOI Search in Google Scholar Back to article
Trindade GC, Viggiano LGL, Brant ER, et al. Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires. Hematol Transfus Cell Ther 2019; 41(4): 335–341. doi: 10.1016/j.htct.2019.03.010.
Open DOI Search in Google Scholar Back to article
Mahlangu J, Oldenburg J, Callaghan MU, et al. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia 2019; 25(3): 382–391. doi: 10.1111/hae.13731.
Open DOI Search in Google Scholar Back to article
Oldenburg J, Tran H, Peyvandi F, et al. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia 2021; 27(3): 398–407. doi: 10.1111/hae.14270.
Open DOI Search in Google Scholar Back to article
von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388(4): 310–318. doi: 10.1056/NEJMoa2209226.
Open DOI Search in Google Scholar Back to article
Hermans C, Reding MT, Astermark J, Klamroth R, Mancuso ME. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician’s perspective. Crit Rev Oncol Hematol 2022; 174: 103678. doi: 10.1016/j.critrevonc.2022.103678.
Open DOI Search in Google Scholar Back to article
Blair HA. Emicizumab: a review in haemophilia A. Drugs 2019; 79(15): 1697–1707. doi: 10.1007/s40265-019-01200-2.
Open DOI Search in Google Scholar Back to article
Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117(7): 1348–1357. doi: 10.1160/TH17-01-0030.
Open DOI Search in Google Scholar Back to article
Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25(1): 33–44. doi: 10.1111/hae.13618.
Open DOI Search in Google Scholar Back to article
Young G, Liesner R, Chang T, et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127–2138. doi: 10.1182/blood.2019001869.
Open DOI Search in Google Scholar Back to article
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–822. doi: 10.1056/NEJMoa1803550.
Open DOI Search in Google Scholar Back to article
Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 2019; 25(6): 979–987. doi: 10.1111/hae.13848.
Open DOI Search in Google Scholar Back to article
Yang R, Wang S, Wang X, et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemostast 2022; 6(2): e12670. doi: 10.1002/rth2.12670.
Open DOI Search in Google Scholar Back to article
Négrier C, Mahlangu J, Lehle M, et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol 2023; 10(3): e168–e177. doi: 10.1016/S2352-3026(22)00377-5.
Open DOI Search in Google Scholar Back to article
Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood 2024; 143(14): 1355–1364. doi: 10.1182/blood.2023021832.
Open DOI Search in Google Scholar Back to article
European Medicines Agency. HEMLIBRA^® solution for injection: Emicizumab. [Initial EU approval: 2018.] 2023. Available from https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf (accessed November 2024).
Search in Google Scholar Back to article
Skinner MW, Negrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27(5): 854–865. doi: 10.1111/hae.14363.
Open DOI Search in Google Scholar Back to article
Hassan AS, Sherief LM, Hamdy M, Salamah A, El-Agamy OA. Physical activity limitations in children with severe haemophilia A. Does emicizumab make a difference? J Pak Med Assoc 2023; 73(Suppl 4): S31–S33. doi: 10.47391/JPMA.EGY-S4-10.
Open DOI Search in Google Scholar Back to article
Oldenburg J, Pipe SW, Mancuso ME, et al. Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP. Current Med Res Opin 2023; 39(2): 219–225. doi: 10.1080/03007995.2022.2116173.
Open DOI Search in Google Scholar Back to article
Thornburg CD, Coffin D. How clinicians and persons with hemophilia may approach shared decision-making. Expert Rev Hematol 2024; 17(6): 193–196. doi: 10.1080/17474086.2024.2353761.
Open DOI Search in Google Scholar Back to article
Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 2004; 24(2): 105–112. doi: 10.1016/j.nedt.2003.10.001.
Open DOI Search in Google Scholar Back to article
Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nursing 2008; 62(1): 107–115. doi: 10.1111/j.1365-2648.2007.04569.x.
Open DOI Search in Google Scholar Back to article
O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 2014; 89(9): 1245–1251. doi: 10.1097/ACM.0000000000000388.
Open DOI Search in Google Scholar Back to article
Björkqvist J, Astermark J, Holme PA, et al. Non-interventional study on health-related quality of life, physical activity and bleeds in severe non-inhibitor hemophilia A patients with a bleeding phenotype on FVIII prophylaxis in the Nordics. Res Pract Thromb Haemost 2024; 8: 363–364.
Search in Google Scholar Back to article
Weller SC, Vickers B, Bernard HR, et al. Open-ended interview questions and saturation. PLoS One 2018; 13(6): e0198606. doi: 10.1371/journal.pone.0198606.
Open DOI Search in Google Scholar Back to article
Oka G, Roussel-Robert V, Levivien C, Lopez I, Pieragostini R. Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy. Haemophilia 2023; 29(3): 709–715. doi: 10.1111/hae.14755.
Open DOI Search in Google Scholar Back to article
Kempton C, Trask P, Parnes A, et al. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia 2021; 27(2): 221–228. doi: 10.1111/hae.14222.
Open DOI Search in Google Scholar Back to article
Fletcher S, Jenner K, Holland M, Khair K. The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me. Health Expect 2022; 25(1): 443–454. doi: 10.1111/hex.13404.
Open DOI Search in Google Scholar Back to article
Oladapo AO, Lu M, Walsh S, O’Hara J, Kauf TL. Inhibitor clinical burden of disease: a comparative analysis of the CHESS data. Orphanet J Rare Dis 2018; 13(1): 198. doi: 10.1186/s13023-018-0929-9.
Open DOI Search in Google Scholar Back to article
Biasoli C, Baldacci E, Coppola A, et al. Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project. Blood Transfus 2022; 20(1): 66–77. doi: 10.2450/2021.0138-21.
Open DOI Search in Google Scholar Back to article
Kiialainen A, Niggli M, Kempton CL, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia 2022; 28(6): 1033–1043. doi: 10.1111/hae.14642.
Open DOI Search in Google Scholar Back to article
DiBenedetti D, Neme D, Pan-Petesch B, et al. Patient experience with efanesoctocog Alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Therapeutics 2024; S0149-2918(24): 272–278. doi: 10.1016/j.clinthera.2024.09.010.
Open DOI Search in Google Scholar Back to article
Lattimore SU, Hofstetter MT. Patient and family engagement during treatment change to emicizumab at a hemophilia treatment center. Blood 2019; 134(Supplement 1): :5796. doi: 10.1182/blood-2019-131030.
Open DOI Search in Google Scholar Back to article
Valentino LA BV, Negrier C, O’Mahony B, Bias V, Sannie T, Skinner MW. Personalising haemophilia management with shared decision making. J Haem Pract. 2021; 8(1): 69–79. doi: 10.17225/jhp00178.
Open DOI Search in Google Scholar Back to article
van Balen EC, Wesselo ML, Baker BL, et al. Patient perspectives on novel treatments in haemophilia: A qualitative study. Patient 2020; 13(2): 201–210. doi: 10.1007/s40271-019-00395-6.
Open DOI Search in Google Scholar Back to article
Martinoli C, Della Casa Alberighi O, Di Minno G, et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109(6): 1170–1179. doi: 10.1160/TH12-11-0874.
Open DOI Search in Google Scholar Back to article